Hands-Free
Autoinjector
and
Osmotic Wearable
Bolus Injector

Osmotic Wearable
Bolus Injector
and
Hands-Free
Autoinjector

Introduction

Osmotic WBI Technology

Utilizing a strong force of nature

For injection of larger pharmaceutical volumes subcutaneously, a low flow rate is needed in order for the tissue to absorb the volume injected. In order to achieve this, complex and expensive drive mechanisms with batteries and electronics are commonly used in larger volume, on-body injectors.

The Subcuject WBI utilizes forward osmosis technology to generate force. In simplified terms, two chambers of liquid are separated by a semipermeable membrane. Adding salt to one chamber draws in liquid from the other chamber and hydraulic/mechanical pressure for driving the plunger in the primary drug container is generated. Simple and at a low cost.

Osmosis is a basic and strong force of nature.

Pending patents cover core and peripheral functionality.

Osmotic WBI Value Proposition

  • Few parts
  • No moving parts
  • No electronics

  • Standard primary packaging materials
  • Glass cartridge with septum
  • Standard plunger compound

  • Compared with electromechanical wearables
  • Salt and water
  • No electronics or batteries to dispose

Hands-free Autoinjector value proposition

Alternative to conventional handheld autoinjectors, The autoinjector is adhered to the skin as opposed to being handheld during injection.

The Hands-Free Autoinjector covers two distinctly different user needs:

  • Low volume (<1 ml)
    • For patients with dexterity challenges – such as Rheumatoid Arthritis or Multiple Schlerosis who experience challenges operating a conventional autoinjector – even for fast injections below 1 ml (data from proprietary user studies)
  • Medium volume (2-5 ml):
    • Eliminating the need to hold a conventional autoinjector in steady for a longer period of time

  • Few parts

  • Standard primary packaging materials
  • Glass cartridge with septum
  • Standard plunger compound
  • No excessive force on drug

Development

  • Osmotic WBI
    • Ready for drug specific development
    • The current version can deliver up to 5 ml
    • Can be developed for higher volumes
  • Hands-Free Autoinjector
    • Ready for drug specific development
    • The current version can deliver up to 3 ml
    • Can be developed for higher volumes (5 ml) or for lower volumes (<1 ml)

Why

  • Many new biologics are in development by pharma companies
  • There is a trend towards less frequent drug administration and patient self administration of injections at home
  • This is driving a new class of injectors: wearable bolus injectors (WBI) – also called on-body injectors (OBI) or large volume injectors (LVI)
  • Subcuject is developing a simple WBI injector, using osmosis (salt and water) as the driving engine
  • As an alternative to conventional hand-held autoinjectors, Subcuject is also developing a Hands-Free Autoinjector which is driven by a spring

About us

  • TJCC ApS is owned by the founders and management of the former Subcuject ApS
  • TJCC ApS has acquired all assets from Subcuject ApS that was instigated in 2017
  • TJCC ApS/Subcuject aims to provide better patient care by licensing the product IP to pharma companies developing combination products (drug/device)

Management

Tomas Gundberg

CEO

Design and test engineer with more than 20 years of experience and with own development toolshop. Previous involvement in development of a large number of innovative medical devices including infusion sets and patch pumps.
+45 29681668
gundberg@mail.dk
Claus Schmidt Møller inventor, Founder and CTO

Claus Schmidt Møller

Inventor

B. Sc. Mechanical Engineering. 20+ years of track record in innovation of drug delivery devices. Inventor of Novopen 4 & 5 and co-inventor of Flexpen and Flextouch for Novo Nordisk. Several inventions of various medical devices made for or licensed to major Pharma and drug delivery companies. Mentioned as inventor or co-inventor on 60+ patent families.
+45 2773 6420
csm@c-p-u.dk

Jesper Roested

20+ years experience in business development, management and venture financing within medtech and life sciences. MSc. In Medical Electronics & Physics. Previously Partner at VF Venture investing in- and development of medtech companies. CEO of DDD-Diagnostic (nuclear medicine scanners), multiple positions at Novo Nordisk (in drugs and devices) and McKinsey & Co.
+45 21227772
jesper@roested.dk

Claus Demant

Extensive international experience in sales, business development and leadership from Consumer Tech & Healthcare Industries. Executive MBA, from CBS-SIMI. Global Business Development in Bang & Olufsen and European Regional Director position for Business Development at Novo Nordisk (Obesity). Mentor for startups at DTU Science Park and co-founder of several new companies
+45 60434245
claus_demant@hotmail.com

News and Media

Contact

  • The Subcuject WBI and the Hands-Free Autoinjector are designed for drug/device combinations products, requiring combined development for the specific drug.
  • Please contact us for discussing your needs.

Jesper Roested

Phone: +45 2122 7772
jesper@roested.dk

TJCC ApS

Vinkelvej 4
DK-4130, Assendloese, Viby Sj
Denmark
VAT no: DK-44888092